Duration of Adjuvant Trastuzumab in HER2 Positive Breast Cancer: Overall and Disease Free Survival Results from Meta-Analyses of Randomized Controlled Trials

Discovery of trastuzumab has revolutionized the outcome of Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer, a historically aggressive subtype with particularly poor prognosis before the availability of HER2 targeted therapy.[1] Approval of 1 year of trastuzumab by the United States Food and Drug Administration (FDA) for adjuvant treatment of early stage breast cancer in 2006 was paradigm shifting. This decision was supported by results from pivotal Randomized Controlled Trials (RCTs) using trastuzumab for one year for pragmatic reasons rather than due to prior evidence or scientific rationale.

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2wpGips
via IFTTT